Literature DB >> 6224880

Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.

G D Ross, S L Newman, J D Lambris, J E Devery-Pocius, J A Cain, P J Lachmann.   

Abstract

The many different recognized functions of C3 are dependent upon the ability of the activated C3 molecule both to bind covalently to protein and carbohydrate surfaces and to provide binding sites for as many as eleven different proteins. The location of the binding sites for six of these different proteins (factors B and H, complement receptors CR(1), CR(2) and CR(3) and conglutinin) was examined in the naturally occurring C3-fragments generated by C3 activation (C3b) and degradation by Factor I (iC3b, C3c, C3d,g) and trypsin (C3d). Evidence was obtained for at least four distinct binding sites in C3 for these six different C3 ligands. One binding site for B was detectable only in C3b, whereas a second binding site for H and CR(1) was detectable in both C3b and iC3b. The affinity of the binding site for H and CR(1) was charge dependent and considerably reduced in iC3b as compared to C3b. H binding to iC3b-coated sheep erythrocytes (EC3bi) was measurable only in low ionic strength buffer (4 mS). The finding that C3c-coated microspheres bound to CR(1), indicated that this second binding site was still intact in the C3c fragment. However, H binding to C3c was not examined. A third binding site in C3 for CR(2) was exposed in the d region by factor I cleavage of C3b into iC3b, and the activity of this site was unaffected by the further I cleavage of iC3b into C3d,g. Removal of the 8,000-dalton C3g fragment from C3d,g with trypsin forming C3d, resulted in reduced CR2 activity. However, because saturating amounts of monoclonal anti-C3g did not block the CR(2)-binding activity of EC3d,g, it appears unlikely that the g region of C3d,g or iC3b forms a part of the CR(2)-binding site. In addition, detergent-solubilized EC3d (C3d-OR) inhibited the CR(2)-binding activity of EC3d,g. Monocytes and neutrophils, that had been previously thought to lack CR(2) because of their inability to form EC3d rosettes, did bind EC3d,g containing greater than 5 x 10(4) C3d,g molecules per E. The finding that monocyte and neutrophil rosettes with EC3d,g were inhibited by C3d-OR, suggested that these phagocytic cells might indeed express very low numbers of CR(2), and that these CR(2) were detectable with EC3d,g and not with EC3d because C3d,g had a higher affinity for CR2 than did C3d. A fourth C3 binding site for CR(3) and conglutinin (K) was restricted to the iC3b fragment. Because of simultaneous attachment of iC3b to phagocyte CR3 and CR(3), the characteristics of iC3b binding to CR3 could only be examined with phagocytes on which the CR(1) had been blocked with anti-CR(1). Inhibition studies with EDTA and N-acetyl-D-glucosamine demonstrated a requirement for both calcium cations and carbohydrate in the binding of EC3bi to CR3 and to K. However, CR(3) differed from K in that magnesium cations were required in addition to calcium for maximum CR(3) binding activity, and NADG produced less inhibition of CR(3) activity than of K activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224880      PMCID: PMC2187331          DOI: 10.1084/jem.158.2.334

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  Immune adherence by the fourth component of complement.

Authors:  N R Cooper
Journal:  Science       Date:  1969-07-25       Impact factor: 47.728

2.  Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.

Authors:  M D Kazatchkine; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

3.  Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies.

Authors:  N J Dobson; J D Lambris; G D Ross
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

4.  Cross-reaction of a rat-anti-mouse phagocyte-specific monoclonal antibody (anti-Mac-1) with human monocytes and natural killer cells.

Authors:  K A Ault; T A Springer
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

5.  C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.

Authors:  Z Fishelson; H J Müller-Eberhard
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

6.  Evidence for presence of an internal thiolester bond in third component of human complement.

Authors:  B F Tack; R A Harrison; J Janatova; M L Thomas; J W Prahl
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

7.  Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody.

Authors:  J D Lambris; N J Dobson; G D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

8.  Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.

Authors:  P J Lachmann; M K Pangburn; R G Oldroyd
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

9.  Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.

Authors:  G D Ross; M J Polley; E M Rabellino; H M Grey
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

10.  Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin.

Authors:  J D Lambris; N J Dobson; G D Ross
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

View more
  55 in total

1.  Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex.

Authors:  Alexander E Aleshin; Richard G DiScipio; Boguslaw Stec; Robert C Liddington
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

2.  Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18.

Authors:  Osama A Hamad; Ioannis Mitroulis; Karin Fromell; Huda Kozarcanin; Triantafyllos Chavakis; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Thromb Haemost       Date:  2015-08-13       Impact factor: 5.249

3.  Ligation of membrane immunoglobulin leads to inactivation of the signal-transducing ability of membrane immunoglobulin, CD19, CD21, and B-cell gp95.

Authors:  G T Rijkers; A W Griffioen; B J Zegers; J C Cambier
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

4.  Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia.

Authors:  J A Tooze; D H Bevan
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

5.  Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).

Authors:  G R Nemerow; R Wolfert; M E McNaughton; N R Cooper
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

6.  Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.

Authors:  J D Lambris; V S Ganu; S Hirani; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

7.  Opsonized streptococcal cell walls cross-link human leukocytes and erythrocytes by complement receptors.

Authors:  K B Pryzwansky; J D Lambris; E K MacRae; J H Schwab
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

8.  Isolation of complement-fragment-iC3b-binding proteins by affinity chromatography. The identification of p150,95 as an iC3b-binding protein.

Authors:  K J Micklem; R B Sim
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

9.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Authors:  Yvonne Klapper; Osama A Hamad; Yuji Teramura; Gero Leneweit; G Ulrich Nienhaus; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Biomaterials       Date:  2014-01-23       Impact factor: 12.479

10.  Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.

Authors:  Kazi Abdus Salam; Richard Y Wang; Teresa Grandinetti; Valeria De Giorgi; Harvey J Alter; Robert D Allison
Journal:  Hepatology       Date:  2018-11-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.